Anti-breast cancer potential of a new xanthine derivative: in silico, antiproliferative, selectivity, VEGFR-2 inhibition, apoptosis induction and migration inhibition studies

[1]  Ibrahim M. Ibrahim,et al.  Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach , 2023, Antiviral therapy.

[2]  Łukasz Szeleszczuk,et al.  Review of Applications of Density Functional Theory (DFT) Quantum Mechanical Calculations to Study the High-Pressure Polymorphs of Organic Crystalline Materials , 2023, International journal of molecular sciences.

[3]  Junfei Gu,et al.  Editorial: Exploring the therapeutic effects of synthetic, semi-synthetic and naturally derived compounds against cancer , 2023, Frontiers in pharmacology.

[4]  Ibrahim M. Ibrahim,et al.  Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducers. , 2023, Computational biology and chemistry.

[5]  Ibrahim M. Ibrahim,et al.  Identification of new theobromine-based derivatives as potent VEGFR-2 inhibitors: design, semi-synthesis, biological evaluation, and in silico studies , 2023, RSC advances.

[6]  Ibrahim M. Ibrahim,et al.  New theobromine derivatives inhibiting VEGFR-2: design, synthesis, antiproliferative, docking and molecular dynamics simulations. , 2023, Future medicinal chemistry.

[7]  S. Ekins,et al.  Comparing LD50/LC50 Machine Learning Models for Multiple Species. , 2023, Journal of chemical health & safety.

[8]  Wagdy M. Eldehna,et al.  Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative, docking and MD simulation studies. , 2023, Journal of biomolecular structure & dynamics.

[9]  Ibrahim M. Ibrahim,et al.  (E)-N-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide: A Novel Pyridine Derivative for Inhibiting Vascular Endothelial Growth Factor Receptor-2: Synthesis, Computational, and Anticancer Studies , 2022, Molecules.

[10]  Ibrahim M. Ibrahim,et al.  In silico, in vitro VEGFR-2 inhibition, and anticancer activity of a 3-(hydrazonomethyl)naphthalene-2-ol derivative , 2022, Journal of biomolecular structure & dynamics.

[11]  Wagdy M. Eldehna,et al.  Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway , 2022, PloS one.

[12]  Wagdy M. Eldehna,et al.  Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies , 2022, Molecules.

[13]  W. Dehaen,et al.  Isolation and In Silico Inhibitory Potential against SARS-CoV-2 RNA Polymerase of the Rare Kaempferol 3-O-(6″-O-acetyl)-Glucoside from Calligonum tetrapterum , 2022, Plants.

[14]  Ibrahim M. Ibrahim,et al.  The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches , 2022, Processes.

[15]  Wagdy M. Eldehna,et al.  Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies , 2022, Journal of enzyme inhibition and medicinal chemistry.

[16]  Tongtong Wang,et al.  Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: disposing of waste with waste , 2022, Environmental Science and Pollution Research.

[17]  W. Dehaen,et al.  Isolation and In Silico SARS-CoV-2 Main Protease Inhibition Potential of Jusan Coumarin, a New Dicoumarin from Artemisia glauca , 2022, Molecules.

[18]  S. Fu,et al.  The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment , 2022, Frontiers in Immunology.

[19]  B. Baradaran,et al.  Exploiting systems biology to investigate the gene modules and drugs in ovarian cancer: A hypothesis based on the weighted gene co-expression network analysis. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  Manuela Pavan,et al.  In Silico Approaches In Carcinogenicity Hazard Assessment: Current Status and Future Needs. , 2021, Computational toxicology.

[21]  P. A. Valiente,et al.  gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. , 2021, Journal of chemical theory and computation.

[22]  Deepa R. Parmar,et al.  Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. , 2021, Bioorganic chemistry.

[23]  T. Tuccinardi.  What is the current value of MM/PBSA and MM/GBSA methods in drug discovery? , 2021, Expert opinion on drug discovery.

[24]  D. Dou,et al.  Traditional ancient Egyptian medicine: A review , 2021, Saudi journal of biological sciences.

[25]  M. Rafraf,et al.  Effectiveness of theobromine on inhibition of 1,2-dimethylhydrazine-induced rat colon cancer by suppression of the Akt/GSK3β/β-catenin signaling pathway , 2020 .

[26]  E. Benfenati,et al.  Integrated in silico models for the prediction of No-Observed-(Adverse)-Effect-Levels and Lowest-Observed-(Adverse)-Effect-Levels in rats for sub-chronic repeated dose toxicity. , 2020, Chemical research in toxicology.

[27]  Kannan R. R. Rengasamy,et al.  Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer , 2020, Medicinal research reviews.

[28]  Michael J. Keiser,et al.  Learning Molecular Representations for Medicinal Chemistry. , 2020, Journal of medicinal chemistry.

[29]  A. Mazurek,et al.  Periodic DFT Calculations—Review of Applications in the Pharmaceutical Sciences , 2020, Pharmaceutics.

[30]  A. Foroumadi,et al.  A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. , 2020, Bioorganic chemistry.

[31]  Thanigaimalai Pillaiyar,et al.  A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery , 2020, European Journal of Medicinal Chemistry.

[32]  A. Dimberg,et al.  Tumor angiogenesis: causes, consequences, challenges and opportunities , 2019, Cellular and Molecular Life Sciences.

[33]  D. Pérez-Pérez,et al.  Methylxanthines: Potential Therapeutic Agents for Glioblastoma , 2019, Pharmaceuticals.

[34]  R. Williams,et al.  Generation of TD50 values for carcinogenicity study data. , 2019, Toxicology research.

[35]  S. Dimmitt,et al.  Why maximum tolerated dose? , 2019, British journal of clinical pharmacology.

[36]  V. Kulkarni,et al.  Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective , 2019, Medicine in Drug Discovery.

[37]  A. Metwaly,et al.  Black Ginseng and Its Saponins: Preparation, Phytochemistry and Pharmacological Effects , 2019, Molecules.

[38]  Adriano D Andricopulo,et al.  ADMET modeling approaches in drug discovery. , 2019, Drug discovery today.

[39]  C. Mariani,et al.  Exploring cocoa properties: is theobromine a cognitive modulator? , 2019, Psychopharmacology.

[40]  Jean-Charles Carvaillo,et al.  TTClust: A Versatile Molecular Simulation Trajectory Clustering Program with Graphical Summaries , 2018, J. Chem. Inf. Model..

[41]  Chaoyang Zhang,et al.  A review on machine learning methods for in silico toxicity prediction , 2018, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[42]  Y. Sakai,et al.  Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway , 2018, International journal of molecular sciences.

[43]  Hongli Liu,et al.  Molecular dynamics simulations and novel drug discovery , 2018, Expert opinion on drug discovery.

[44]  Melissa F. Adasme,et al.  From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction patterns , 2017, Scientific Reports.

[45]  Y. Iwamoto,et al.  Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells , 2017, Scientific Reports.

[46]  Lei Chen,et al.  New knowledge of the mechanisms of sorafenib resistance in liver cancer , 2017, Acta Pharmacologica Sinica.

[47]  W. Glanzner,et al.  Guaraná a Caffeine-Rich Food Increases Oxaliplatin Sensitivity of Colorectal HT-29 Cells by Apoptosis Pathway Modulation. , 2016, Anti-cancer agents in medicinal chemistry.

[48]  A. Cavalli,et al.  Role of Molecular Dynamics and Related Methods in Drug Discovery. , 2016, Journal of medicinal chemistry.

[49]  Rui M. V. Abreu,et al.  Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. , 2015, Bioorganic & medicinal chemistry.

[50]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[51]  Michael Schroeder,et al.  PLIP: fully automated protein–ligand interaction profiler , 2015, Nucleic Acids Res..

[52]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[53]  M. Nilges,et al.  Principal Component Analysis reveals correlation of cavities evolution and functional motions in proteins. , 2015, Journal of molecular graphics & modelling.

[54]  Jennifer E Amon,et al.  An introduction to the wound healing assay using live-cell microscopy , 2014, Cell adhesion & migration.

[55]  N. Sugimoto,et al.  Theobromine, the Primary Methylxanthine Found in Theobroma cacao, Prevents Malignant Glioblastoma Proliferation by Negatively Regulating Phosphodiesterase-4, Extracellular Signal-regulated Kinase, Akt/mammalian Target of Rapamycin Kinase, and Nuclear Factor-Kappa B , 2014, Nutrition and cancer.

[56]  R. Eskander,et al.  Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications. , 2014, Gynecologic oncology.

[57]  Jianping Chen,et al.  Dietary Compound Isoliquiritigenin Inhibits Breast Cancer Neoangiogenesis via VEGF/VEGFR-2 Signaling Pathway , 2013, PloS one.

[58]  Feixiong Cheng,et al.  In silico Prediction of Chemical Ames Mutagenicity , 2012, J. Chem. Inf. Model..

[59]  Andrea Amadei,et al.  Essential dynamics: foundation and applications , 2012 .

[60]  R D Benz,et al.  (Q)SAR Modeling and Safety Assessment in Regulatory Review , 2012, Clinical pharmacology and therapeutics.

[61]  Kyungik Lee,et al.  Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. , 2010, European journal of medicinal chemistry.

[62]  E. Smit,et al.  Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  Christopher Hulme,et al.  The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. , 2010, Bioorganic & medicinal chemistry.

[64]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[65]  Elena Papaleo,et al.  Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: the myoglobin case. , 2009, Journal of molecular graphics & modelling.

[66]  Ji-Xia Ren,et al.  Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. , 2009, Journal of molecular graphics & modelling.

[67]  A. Lavrijsen,et al.  Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. , 2007, European journal of cancer.

[68]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[69]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[70]  Y. Sadzuka,et al.  Effect of methylxanthine derivatives on doxorubicin transport and antitumor activity. , 2001, Current drug metabolism.

[71]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[72]  E. Skopińska-Różewska,et al.  Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. , 2000, Oncology reports.

[73]  E. Skopińska-Różewska,et al.  The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancer cells. , 1998, Oncology reports.

[74]  H. Berendsen,et al.  Essential dynamics of proteins , 1993, Proteins.

[75]  N. El-Deeb,et al.  New theobromine derivative as apoptotic anti-triple-negative breast cancer targeting EGFR protein: CADD story , 2023, Journal of Molecular Structure.

[76]  T. Kassem,et al.  Synthesis, X-ray, Hirshfeld, and AIM Studies on Zn(II) and Cd(II) Complexes with Pyridine Ligands , 2022 .

[77]  M. Taha,et al.  Inhibitory Effects of New Mercapto Xanthine Derivatives in Human mcf7 and k562 Cancer Cell Lines , 2017 .

[78]  H. J. Smit.  Theobromine and the pharmacology of cocoa. , 2011, Handbook of experimental pharmacology.

[79]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[80]  K. Roszkowski,et al.  Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice. , 1993, Folia biologica.